Home ETF List About

Portfolio Holdings Detail for ISIN IE00BYXG2H39
Stock Name / FundiShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
IssuerBlackrock
Entity holding fund iShares IV Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300ZP07LMR36K1T02
ETF TickerBTEC(USD) LSE
ETF TickerBTEK(GBP) LSE
ETF Ticker2B70(EUR) F
ETF Ticker2B70.DE(EUR) CXE
ETF TickerBTEC.LS(USD) CXE
ETF TickerBTEK.LS(GBP) CXE
ETF TickerBTEC.L(GBP) LSE
ETF TickerBTEK.L(GBP) LSE

Holdings detail for OCUL

Stock NameOcular Therapeutix Inc
TickerOCUL(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS67576A1007
LEI529900ABAWFXOHSIHG03

Show aggregate OCUL holdings

News associated with OCUL

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives $17.20 Consensus Target Price from Brokerages
Ocular Therapeutix, Inc. (NASDAQ:OCUL – Get Free Report) has been given an average recommendation of “Buy” by the five ratings firms that are covering the stock, Marketbeat.com reports. Five equities research analysts have rated the stock with a buy rating. The average 12 month price objective among brokerages that have issued ratings on the stock […] - 2025-09-09 02:46:48
XTX Topco Ltd Increases Stock Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)
XTX Topco Ltd raised its position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) by 95.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 22,605 shares of the biopharmaceutical company’s stock after buying an additional 11,012 shares during the quarter. […] - 2025-08-14 04:25:01
Needham & Company LLC Boosts Ocular Therapeutix (NASDAQ:OCUL) Price Target to $15.00
Ocular Therapeutix (NASDAQ:OCUL – Get Free Report) had its target price upped by investment analysts at Needham & Company LLC from $14.00 to $15.00 in a note issued to investors on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Needham & Company LLC’s price target points to a potential […] - 2025-08-07 04:30:57
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives $17.33 Consensus PT from Analysts
Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL – Get Free Report) have been assigned a consensus recommendation of “Buy” from the six analysts that are covering the stock, MarketBeat Ratings reports. Six analysts have rated the stock with a buy rating. The average 1-year target price among brokers that have issued ratings on the stock in […] - 2025-08-07 03:12:45
Ocular Therapeutix (NASDAQ:OCUL) Shares Gap Down Following Weak Earnings
Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL – Get Free Report) gapped down prior to trading on Tuesday following a dissappointing earnings announcement. The stock had previously closed at $12.35, but opened at $11.21. Ocular Therapeutix shares last traded at $11.34, with a volume of 558,460 shares traded. The biopharmaceutical company reported ($0.39) earnings per share […] - 2025-08-07 02:13:01
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Sold by Allianz Asset Management GmbH
Allianz Asset Management GmbH lowered its position in Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) by 41.9% during the first quarter, Holdings Channel.com reports. The fund owned 37,500 shares of the biopharmaceutical company’s stock after selling 27,000 shares during the quarter. Allianz Asset Management GmbH’s holdings in Ocular Therapeutix were worth $275,000 at the end […] - 2025-08-04 05:58:51
Nuveen Asset Management LLC Sells 88,468 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)
Nuveen Asset Management LLC decreased its holdings in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) by 17.6% in the fourth quarter, Holdings Channel.com reports. The firm owned 414,104 shares of the biopharmaceutical company’s stock after selling 88,468 shares during the period. Nuveen Asset Management LLC’s holdings in Ocular Therapeutix were worth $3,536,000 as […] - 2025-06-02 05:04:52
Millennium Management LLC Acquires New Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)
Millennium Management LLC acquired a new stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 447,237 shares of the biopharmaceutical company’s stock, valued at approximately $3,819,000. A number of other hedge […] - 2025-05-30 05:40:53
Bank of America Corp DE Trims Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)
Bank of America Corp DE lessened its stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) by 43.9% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 437,071 shares of the biopharmaceutical company’s stock after selling 341,400 shares during the quarter. Bank […] - 2025-05-30 04:54:54
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Bought by ProShare Advisors LLC
ProShare Advisors LLC raised its position in Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) by 32.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 51,270 shares of the biopharmaceutical company’s stock after purchasing an additional 12,669 shares during the period. […] - 2025-05-28 08:08:48
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Buys 2,853 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) by 3.3% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 88,463 shares of the biopharmaceutical company’s stock after buying an additional 2,853 shares during the quarter. MIRAE […] - 2025-05-28 05:31:02
D. E. Shaw & Co. Inc. Makes New Investment in Ocular Therapeutix, Inc. (NASDAQ:OCUL)
D. E. Shaw & Co. Inc. purchased a new stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) in the fourth quarter, HoldingsChannel reports. The institutional investor purchased 31,419 shares of the biopharmaceutical company’s stock, valued at approximately $268,000. A number of other hedge funds and other institutional investors also recently modified their holdings of […] - 2025-05-28 04:42:56
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Sold by Deutsche Bank AG
Deutsche Bank AG lessened its position in Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) by 45.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 456,120 shares of the biopharmaceutical company’s stock after selling 377,454 shares during the period. Deutsche Bank […] - 2025-05-20 05:12:53
Ocular Therapeutix (NASDAQ:OCUL) Shares Down 6.5% After Analyst Downgrade
Ocular Therapeutix, Inc. (NASDAQ:OCUL – Get Free Report)’s share price fell 6.5% during trading on Tuesday after Needham & Company LLC lowered their price target on the stock from $15.00 to $14.00. Needham & Company LLC currently has a buy rating on the stock. Ocular Therapeutix traded as low as $7.31 and last traded at […] - 2025-05-07 03:05:15
First Trust Advisors LP Makes New Investment in Ocular Therapeutix, Inc. (NASDAQ:OCUL)
First Trust Advisors LP bought a new position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) during the 4th quarter, Holdings Channel reports. The fund bought 212,944 shares of the biopharmaceutical company’s stock, valued at approximately $1,819,000. A number of other institutional investors and hedge funds have also made changes to their positions […] - 2025-05-06 04:58:55
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Acquired by CANADA LIFE ASSURANCE Co
CANADA LIFE ASSURANCE Co lifted its holdings in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) by 152.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 30,227 shares of the biopharmaceutical company’s stock after buying an additional 18,251 […] - 2025-05-01 06:12:45
XTX Topco Ltd Makes New Investment in Ocular Therapeutix, Inc. (NASDAQ:OCUL)
XTX Topco Ltd bought a new stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor bought 11,593 shares of the biopharmaceutical company’s stock, valued at approximately $99,000. Several other hedge funds have also bought and sold shares of OCUL. […] - 2025-04-30 06:12:51
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Sold by Barclays PLC
Barclays PLC decreased its position in Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) by 35.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 331,242 shares of the biopharmaceutical company’s stock after selling 180,280 shares during the period. Barclays PLC’s holdings in Ocular […] - 2025-04-30 05:12:50
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Holdings Cut by Legal & General Group Plc
Legal & General Group Plc lowered its holdings in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) by 8.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 104,783 shares of the biopharmaceutical company’s stock after selling 9,296 shares during the quarter. Legal […] - 2025-04-28 04:56:53
Invesco Ltd. Acquires 134,573 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)
Invesco Ltd. raised its holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) by 17.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 890,046 shares of the biopharmaceutical company’s stock after acquiring an additional 134,573 shares during the period. […] - 2025-04-25 04:58:59
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives $16.38 Average PT from Analysts
Ocular Therapeutix, Inc. (NASDAQ:OCUL – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the eight analysts that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 12 month price […] - 2025-04-04 02:45:04
Cibc World Markets Corp Invests $124,000 in Ocular Therapeutix, Inc. (NASDAQ:OCUL)
Cibc World Markets Corp purchased a new position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) during the 4th quarter, Holdings Channel reports. The institutional investor purchased 14,562 shares of the biopharmaceutical company’s stock, valued at approximately $124,000. Several other large investors have also modified their holdings of the stock. AlphaQuest LLC acquired […] - 2025-03-28 06:18:49
Ocular Therapeutix (NASDAQ:OCUL) Coverage Initiated at Royal Bank of Canada
Equities researchers at Royal Bank of Canada started coverage on shares of Ocular Therapeutix (NASDAQ:OCUL – Get Free Report) in a report released on Tuesday, Marketbeat reports. The firm set an “outperform” rating and a $17.00 price target on the biopharmaceutical company’s stock. Royal Bank of Canada’s price target would indicate a potential upside of […] - 2025-03-20 04:48:56
Needham & Company LLC Begins Coverage on Ocular Therapeutix (NASDAQ:OCUL)
Analysts at Needham & Company LLC initiated coverage on shares of Ocular Therapeutix (NASDAQ:OCUL – Get Free Report) in a report issued on Tuesday, Marketbeat reports. The brokerage set a “buy” rating and a $15.00 price target on the biopharmaceutical company’s stock. Needham & Company LLC’s price objective indicates a potential upside of 77.94% from […] - 2025-03-13 04:22:56
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Given Consensus Rating of “Moderate Buy” by Analysts
Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the six brokerages that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 1 […] - 2025-03-07 05:14:55
Ocular Therapeutix (NASDAQ:OCUL) Shares Gap Down Following Weak Earnings
Ocular Therapeutix, Inc. (NASDAQ:OCUL – Get Free Report) shares gapped down prior to trading on Monday after the company announced weaker than expected quarterly earnings. The stock had previously closed at $7.14, but opened at $6.94. Ocular Therapeutix shares last traded at $6.45, with a volume of 361,162 shares changing hands. The biopharmaceutical company reported […] - 2025-03-05 04:34:51
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Acquired by New York State Common Retirement Fund
New York State Common Retirement Fund lifted its stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) by 18.4% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 98,097 shares of the biopharmaceutical company’s stock after purchasing an additional 15,239 shares during the quarter. New York State Common Retirement Fund’s holdings in […] - 2025-03-04 07:17:07
Investors Buy High Volume of Call Options on Ocular Therapeutix (NASDAQ:OCUL)
Ocular Therapeutix, Inc. (NASDAQ:OCUL – Get Free Report) was the target of unusually large options trading activity on Monday. Stock traders bought 7,643 call options on the stock. This represents an increase of approximately 1,707% compared to the typical volume of 423 call options. Ocular Therapeutix Price Performance Shares of NASDAQ OCUL opened at $5.93 […] - 2025-03-04 06:44:54
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Stock Position Lifted by Rhumbline Advisers
Rhumbline Advisers increased its holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) by 2.7% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 213,601 shares of the biopharmaceutical company’s stock after buying an additional 5,682 shares during the period. Rhumbline Advisers’ holdings in Ocular Therapeutix were worth $1,824,000 as of its most recent […] - 2025-03-04 06:12:53
Analysts See 19% Gains Ahead For FYX
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-01-30 10:31:08

iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) OCUL holdings

DateNumber of OCUL Shares HeldBase Market Value of OCUL SharesLocal Market Value of OCUL SharesChange in OCUL Shares HeldChange in OCUL Base ValueCurrent Price per OCUL Share HeldPrevious Price per OCUL Share Held
2025-11-11 (Tuesday)111,654USD 1,252,758USD 1,252,758
2025-11-10 (Monday)111,654OCUL holding increased by 286USD 1,209,213OCUL holding increased by 870USD 1,209,213286USD 870 USD 10.83 USD 10.85
2025-11-07 (Friday)111,368USD 1,208,343OCUL holding increased by 24501USD 1,208,3430USD 24,501 USD 10.85 USD 10.63
2025-11-06 (Thursday)111,368OCUL holding increased by 286USD 1,183,842OCUL holding decreased by -16954USD 1,183,842286USD -16,954 USD 10.63 USD 10.81
2025-11-05 (Wednesday)111,082USD 1,200,796OCUL holding decreased by -9998USD 1,200,7960USD -9,998 USD 10.81 USD 10.9
2025-11-04 (Tuesday)111,082OCUL holding increased by 288USD 1,210,794OCUL holding decreased by -53366USD 1,210,794288USD -53,366 USD 10.9 USD 11.41
2025-11-03 (Monday)110,794USD 1,264,160OCUL holding decreased by -27698USD 1,264,1600USD -27,698 USD 11.41 USD 11.66
2025-10-31 (Friday)110,794USD 1,291,858OCUL holding decreased by -17727USD 1,291,8580USD -17,727 USD 11.66 USD 11.82
2025-10-30 (Thursday)110,794OCUL holding increased by 1440USD 1,309,585OCUL holding increased by 54201USD 1,309,5851,440USD 54,201 USD 11.82 USD 11.48
2025-10-29 (Wednesday)109,354OCUL holding increased by 576USD 1,255,384OCUL holding increased by 1174USD 1,255,384576USD 1,174 USD 11.48 USD 11.53
2025-10-28 (Tuesday)108,778USD 1,254,210OCUL holding decreased by -2176USD 1,254,2100USD -2,176 USD 11.53 USD 11.55
2025-10-27 (Monday)108,778USD 1,256,386OCUL holding increased by 6527USD 1,256,3860USD 6,527 USD 11.55 USD 11.49
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of OCUL by Blackrock for IE00BYXG2H39

Show aggregate share trades of OCUL

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-11-10BUY28611.07010.680 10.719USD 3,066 9.17
2025-11-06BUY28610.93010.600 10.633USD 3,041 9.15
2025-11-04BUY28811.35510.400 10.495USD 3,023 9.13
2025-10-30BUY1,44012.10011.490 11.551USD 16,633 9.09
2025-10-29BUY57611.48011.695 11.673USD 6,724 9.08
2025-10-22SELL-1,14811.34011.840 11.790USD -13,535 9.02 Loss of -3,184 on sale
2025-10-20BUY57412.18012.220 12.216USD 7,012 8.98
2025-10-17BUY1,43311.84012.160 12.128USD 17,379 8.97
2025-10-15BUY2,28011.93511.940 11.939USD 27,222 8.95
2025-10-03BUY2,01611.41011.770 11.734USD 23,656 8.93
2025-10-02BUY28811.06011.220 11.204USD 3,227 8.91
2025-09-30BUY57411.69012.880 12.761USD 7,325 8.89
2025-09-26BUY57412.53012.970 12.926USD 7,420 8.84
2025-09-25BUY57412.24012.640 12.600USD 7,232 8.82
2025-09-24BUY4,56712.56012.780 12.758USD 58,266 8.80
2025-09-18BUY27412.71012.755 12.751USD 3,494 8.78
2025-09-17BUY82512.16512.700 12.646USD 10,433 8.76
2025-08-20SELL-1,09611.96012.340 12.302USD -13,483 8.68 Loss of -3,972 on sale
2025-07-30BUY1,09211.66012.205 12.150USD 13,268 8.55
2025-07-17SELL-54611.38011.540 11.524USD -6,292 8.36 Loss of -1,730 on sale
2025-07-11SELL-2,19211.03011.310 11.282USD -24,730 8.28 Loss of -6,581 on sale
2025-07-07BUY8229.6109.666 9.660USD 7,941 8.22
2025-07-02BUY15,0709.4609.600 9.586USD 144,461 8.20
2025-06-20BUY4,5118.1308.410 8.382USD 37,811 8.20
2025-06-11BUY5208.8209.183 9.147USD 4,756 8.18
2025-06-10BUY5208.9109.410 9.360USD 4,867 8.18
2025-06-04SELL-2608.3808.490 8.479USD -2,205 8.16 Loss of -83 on sale
2025-04-23BUY2607.8508.230 8.192USD 2,130 8.32
2025-04-10SELL-2,0806.4056.800 6.761USD -14,062 8.42 Profit of 3,455 on sale
2025-04-08SELL-2606.0206.740 6.668USD -1,734 8.47 Profit of 468 on sale
2025-04-07SELL-2606.3006.610 6.579USD -1,711 8.49 Profit of 497 on sale
2025-04-04SELL-1,3006.3557.080 7.007USD -9,110 8.52 Profit of 1,963 on sale
2025-04-01BUY1,0766.5407.410 7.323USD 7,880 8.56
2025-03-31SELL-7837.3307.470 7.456USD -5,838 8.57 Profit of 873 on sale
2025-03-21BUY3,4167.5107.550 7.546USD 25,777 8.65
2025-03-14SELL-4,0167.7208.140 8.098USD -32,522 8.72 Profit of 2,484 on sale
2025-03-07SELL-5027.5407.650 7.639USD -3,835 8.77 Profit of 568 on sale
2025-03-04SELL-2526.5006.630 6.617USD -1,667 8.86 Profit of 564 on sale
2025-02-25BUY5046.7706.920 6.905USD 3,480 9.04
2025-02-19SELL-2507.3807.390 7.389USD -1,847 9.18 Profit of 448 on sale
2025-02-13BUY7477.4807.660 7.642USD 5,709 9.33
2025-02-12BUY2497.4557.510 7.505USD 1,869 9.37
2025-02-11BUY9967.4407.530 7.521USD 7,491 9.41
2024-12-30SELL-7,4328.3508.440 8.431USD -62,659 10.10 Profit of 12,429 on sale
2024-11-18SELL-4,0088.6909.200 9.149USD -36,669 10.91 Profit of 7,041 on sale
2024-11-08SELL-26711.10011.100 11.100USD -2,964 10.91 Loss of -50 on sale
2024-10-21SELL-26811.37011.600 11.577USD -3,103 0.00 Loss of -3,103 on sale
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of OCUL

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19199,2681,000563,05235.4%
2025-09-18200,9630877,76722.9%
2025-09-17202,7580593,70834.2%
2025-09-16269,64201,012,78426.6%
2025-09-15315,71601,015,68831.1%
2025-09-12257,1810449,33157.2%
2025-09-11235,21553393,20459.8%
2025-09-10353,6910661,75153.4%
2025-09-09361,8821,400905,14240.0%
2025-09-08559,7410895,71362.5%
2025-09-051,246,9122,9911,994,81562.5%
2025-09-04731,06512,2261,009,96172.4%
2025-09-03971,6131761,686,75357.6%
2025-09-02297,4954,800924,80632.2%
2025-08-29573,2121,1161,118,41951.3%
2025-08-28409,1310736,25355.6%
2025-08-27417,0947511,039,25240.1%
2025-08-26223,4240618,16736.1%
2025-08-25130,190100294,48844.2%
2025-08-22154,20334,249426,12836.2%
2025-08-21165,85410,809442,26737.5%
2025-08-20218,1270724,34030.1%
2025-08-19188,78263775,48524.3%
2025-08-18236,1291,100977,72724.2%
2025-08-15247,57410,800629,48539.3%
2025-08-14213,8619,244601,76435.5%
2025-08-13315,39048,9861,056,99629.8%
2025-08-12413,11710,4411,133,94736.4%
2025-08-11442,6764,5711,061,48741.7%
2025-08-08549,3703181,002,25454.8%
2025-08-07703,18501,109,18863.4%
2025-08-06586,34375,2321,438,85040.8%
2025-08-051,091,44395,1471,920,72856.8%
2025-08-04493,42740,915766,31264.4%
2025-08-01314,220128684,92845.9%
2025-07-31331,687125585,77756.6%
2025-07-30282,0200523,03053.9%
2025-07-29270,281400674,77740.1%
2025-07-28347,1220895,60038.8%
2025-07-25327,6080641,32151.1%
2025-07-24286,9875,057447,38464.1%
2025-07-23369,5003,513608,53560.7%
2025-07-22301,320700497,20060.6%
2025-07-21402,7936,4181,200,63233.5%
2025-07-18322,74514630,24151.2%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.